During the past decade, there has been an increasing interest in the use of IL-17 inhibitors (such as secukinumab, ixekizumab, and brodalumab) in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis [11]. This evidence concerns the gene IL17A and ankylosing spondylitis.